Mirabilis Medica Closes $10.5 Million Series A Extension to Commercialize Non-Invasive Treatment of Uterine Fibroids
8/21/2007 6:10:49 AM
SEATTLE--(BUSINESS WIRE)--Mirabilis Medica, a privately held medical device company, today announced the closing of a $10.5 million extension to its series A financing, which was originally led by Charter Life Sciences and vSpring Capital last year. The series A extension was led by Arboretum Ventures of Ann Arbor MI, and included Split Rock Partners, Dow Venture Capital, and an individual investor. The funding will be used to continue developing and testing its image-guided High Intensity Focused Ultrasound (HIFU) system for treatment of gynecological diseases.
comments powered by